CITIUS ONCOLOGY INC
CTOR · NASDAQ
Updated at 2026-10-14 09:20:46
- Today's High
- $0.84
- Today’s Low
- $0.74
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $0.85
- Previous Close
- $0.81
- Volume
- 67.95K
- Market Cap
- $75.55M
- P/E Ratio
- --
- EPS
- $-0.47
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- DRUG MANUFACTURERS - SPECIALTY & GENERIC
- Headquarters
- 11 COMMERCE DRIVE, CRANFORD, NJ, UNITED STATES, 07016
- Country
- US
- Listing Date
- 2022-10-14
- Fiscal Year End
- September
- Shares Outstanding
- 92.98M
- CIK
- 0001851484
- Website
- citiusonc.com
Citius Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies tailored for underserved patient populations. With a robust pipeline of proprietary technologies, Citius aims to enhance treatment efficacy and safety across various cancer indications. The company is strategically advancing its promising drug candidates through pivotal clinical trials and regulatory processes, leveraging partnerships and rigorous clinical research standards to optimize patient outcomes and address critical needs in the oncology sector.
Financial Metrics
Revenue
2026-06-30
$1.49M
2026-03-31
$1.66M
2025-12-31
$3.94M
2025-09-30
$0
Operating Expenses
2026-06-30
$7.99M
2026-03-31
$29.95M
2025-12-31
$8.4M
2025-09-30
$4.71M
Net Income
2026-06-30
-$8.92M
2026-03-31
-$26.6M
2025-12-31
-$5.53M
2025-09-30
-$4.99M
Net Profit Margin
2026-06-30
-597.39%
2026-03-31
-1.59K%
2025-12-31
-140.31%
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.08
2026-03-31
$-0.27
2025-12-31
$-0.06
2025-09-30
$-0.06
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$6.99M
2026-03-31
-$26.8M
2025-12-31
-$4.65M
2025-09-30
-$4.67M
Effective Tax Rate
2026-06-30
1.18%
2026-03-31
0.86%
2025-12-31
-5.01%
2025-09-30
-5.58%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $1.49M | $1.66M | $3.94M | $0 |
| Operating Expenses | $7.99M | $29.95M | $8.4M | $4.71M |
| Net Income | -$8.92M | -$26.6M | -$5.53M | -$4.99M |
| Net Profit Margin | -597.39% | -1.59K% | -140.31% | -- |
| Earnings Per Share | $-0.08 | $-0.27 | $-0.06 | $-0.06 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$6.99M | -$26.8M | -$4.65M | -$4.67M |
| Effective Tax Rate | 1.18% | 0.86% | -5.01% | -5.58% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.